Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (23715)	5/21/2007 5:54:14 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Of course the reported finding here ("increase risk of death by 64%") is the other side of an oft criticized pharma coin. It's often the case that pharma studies tout say a statistically significant 50% decreased risk of bad effect x without also disclosing that the risk of x was very low to begin with. The bottom line is that you can get statistically significant effects that have little practical impact. This holds for both positive and adverse effects of a drug. Unfortunately statistical significance (at the magical .05 level) has become the single touchstone for analysis. Peter